Karyopharm Therapeutics Inc KPTI:NASDAQ

Last Price$16.50NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/24/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$16.40 (2)
Ask (Size)$17.00 (10)
Day Low / HighN/A - N/A
Volume1.5 M
 

View Biotechnology IndustryPeer Comparison as of 01/24/2020

 

Karyopharm Therapeutics Inc ( NASDAQ )

Price: $16.50
Change: -0.84 (4.84%)
Volume: 1.5 M
4:00PM ET 1/24/2020
 
 

OPKO Health Inc ( NASDAQ )

Price: $1.58
Change: -0.04 (2.47%)
Volume: 5.1 M
4:00PM ET 1/24/2020
 
 

Dermira Inc ( NASDAQ )

Price: $18.71
Change: -0.05 (0.27%)
Volume: 4.5 M
4:00PM ET 1/24/2020
 
 

NanoString Technologies Inc ( NASDAQ )

Price: $28.12
Change: -1.47 (4.98%)
Volume: 250.7 K
4:00PM ET 1/24/2020
 
 

Luminex Corp ( NASDAQ )

Price: $22.51
Change: -0.02 (0.11%)
Volume: 207.1 K
4:00PM ET 1/24/2020
 

Read more news Recent News

--Analyst Actions: Wedbush Downgrades Karyopharm Therapeutics to Neutral From Outperform, Lifts Price Target to $19 From $18
7:23AM ET 1/17/2020 MT Newswires

Price: 18.83, Change: +0.43, Percent Change: +2.34 ...

Analyst Actions: HC Wainwright Lifts Price Target on Karyopharm Therapeutics to $37 From $36, Reiterates Buy Rating
11:02AM ET 1/14/2020 MT Newswires

Karyopharm Therapeutics (KPTI) has an average analyst rating of buy, with an average price target of $22. Price: 17.30, Change: +0.06, Percent Change:...

Karyopharm Preliminary Q4 Sales Beats Street, FY19 Product Sales Falls Short; Shares Decline
3:54PM ET 1/13/2020 MT Newswires

Karyopharm (KPTI), an oncology-focused pharmaceutical company, said on Monday that it expects Q4 product sales of Xpovio to be in between $17 million and...

Karyopharm Submits Application for Xpovio as Treatment for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
10:45AM ET 12/23/2019 MT Newswires

Karyopharm Therapeutics (KPTI) said Monday that it has submitted a new-drug application to seek the US Food and Drug Administration's accelerated approval...

View all Commentary and Analysis

The Cutting Edge Of Systematic Investing
12:48PM ET 1/21/2020 Seeking Alpha

Karyopharm Therapeutics (KPTI) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow
1:22PM ET 1/15/2020 Seeking Alpha

Biotech Bonanza: 2020 Outlook In An Election Year
4:15PM ET 1/08/2020 Seeking Alpha

2 Small Biotech Stocks To Buy For 2020
11:11AM ET 12/26/2019 Seeking Alpha

Company Profile

Business DescriptionKaryopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA. View company web site for more details
Address85 Wells Avenue
Newton, Massachusetts 02459
Phone+1.617.658.0600
Number of Employees332
Recent SEC Filing01/13/20204
Chief Executive Officer & DirectorMichael G. Kauffman
President & Chief Scientific OfficerSharon Shacham
Vice President-OperationsRonit Milstein
Treasurer, Chief Financial & Accounting OfficerMike Mason

Company Highlights

Price Open$17.40
Previous Close$17.34
52 Week Range$3.92 - 20.09
Market Capitalization$1.0 B
Shares Outstanding62.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/27/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.42
Beta vs. S&P 500N/A
Revenue$30.3 M
Net Profit Margin-909.24%
Return on Equity-187.25%

Analyst Ratings as of 01/15/2020

Buy
6
Overweight
1
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset